ClinicalTrials.gg
RecruitingNCT07136909French OSA18Updated Jul 1, 2026

Validation of the French Version of the OSA-18 Questionnaire

An observational study in Apnea, Obstructive, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon — 6 open to participants now, 7 under way, none of them phase 3. Sleep Apnea, Obstructive · Hospices Civils de Lyon.

Started
2026
with 5 others
Observational
4 of 11
2 open now
Registered
6th of 11
by date

Among the 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon, this one is one of 6 that started in 2026, is one of 4 observational ones, and was the 6th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Sleep Apnea, Obstructive by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is characterized by repetitive partial and/or total closure of the upper airway during sleep, inducing oxygen desaturation and sleep disturbance. Its prevalence in the pediatric population is 1-5%. In children, OSA can have negative consequences on the cardiovascular system and on the neurocognitive development. It is essential to diagnose OSA and to treat it efficiently.

The OSA-18 questionnaire assesses the symptômes of OSA in children and its repercussions. It is composed of 18 items scored on a Likert scale by caregivers. This system allows a more sensitive scoring than binary answers available in other questionnaires like the Pediatric Sleep Questionnaire.

The OSA-18 questionnaire would thus be an interesting tool to use for evaluating treatment efficacy in interventional studies and in clinical practice.

This questionnaire is not yet available in French. The main objective of this study is thus to evaluate the validity of a French version compared to the gold standard method to evaluate OSA: polysomnography.

03

Conditions studied

  • Apnea, Obstructive

Keywords

  • Obstructive sleep apnea
  • sleep disordered breathing
  • questionnaire
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children aged 4 to 17 years referred hospitalized in the sleep unit of the Hospices Civils de Lyon (France) for polysomnography, for a duration of 24 to 48h.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children hospitalized in the Clinical Epileptology, Sleep Disorders, and Child Functional Neurology Department for polysomnography to screen for OSA,
  • Aged 4 to 17 years inclusive.

Exclusion criteria

Exclusion Criteria:

  • Parents and/or children object to participation in the study.
  • Subjects participating in another intervention research study with an ongoing exclusion period.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children referred to the sleep clinic for polysomnography.

    Children aged 4 to 17 years referred hospitalized in the sleep unit of the Hospices Civils de Lyon (France) for polysomnography, for a duration of 24 to 48h.

    Other: Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.

Interventions

  • OtherCompletion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.

    Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.

06

What researchers measure

Primary outcomes

  1. Scores on the French version of the OSA-18 questionnaire (total score)

    The OSA-18 questionnaire will be filled-in by caregivers.

    Time frame: Day 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 19 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 22, 2025
StartActual
Jun 29, 2026
Primary completionEst.
Jan 29, 2028
CompletionEst.
Jan 29, 2028
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136909
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Jun 29, 2026
Primary completion
Jan 29, 2028 (estimated)
Completion
Jan 29, 2028 (estimated)
Last update
Jul 1, 2026

Study contacts

Patricia FRANCO, MD
Contact
patricia.franco@chu-lyon.fr
04 27 85 60 52 ext. +33
Aurore GUYON
Contact
aurore.guyon@chu-lyon.fr
04 27 85 52 47 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion